WHEA:LSE:LSE-SPDR® MSCI World Health Care UCITS ETF (USD)

ETF | Others |

Last Closing

USD 64.425

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 544.83B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 544.83B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 209.75B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B
0R24:LSE Intel Corp.

N/A

USD 196.14B

ETFs Containing WHEA:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.51% 87% B+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.51% 86% B+ 77% C+
Trailing 12 Months  
Capital Gain 13.68% 76% C+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.68% 75% C 71% C-
Trailing 5 Years  
Capital Gain 68.94% 84% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.94% 82% B 82% B
Average Annual (5 Year Horizon)  
Capital Gain 9.43% 66% D+ 69% C-
Dividend Return 9.43% 66% D+ 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.19% 65% D 79% B-
Risk Adjusted Return 92.56% 92% A 95% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike